ATLANTA, GA. – A team from Emory University’s School of Medicine has established striking efficacy of Riptide Bioscience proprietary peptide, RP832c, in both in vitro and in vivo models of cutaneous T-cell lymphoma.
Writing in the Journal of Investigative Dermatology, a team led by Dr. Neda Nikbakht, MD/PhD, reported that in experiments conducted at Emory and at the Thomas Jefferson University School of Medicine, RP832c showed substantial promise as a therapeutic option for cutaneous lymphoma patients.
In the team’s in vitro investigations, macrophages were cultured with human lymphoma cells, dramatically raising the level of the therapeutic target CD206, which is strongly predictive of cancer mortality. Introducing RP832c substantially reduced CD206. Based on this result, the team went on to study lymphoma tumors in mice, finding that CD206 was significantly reduced by RP832 treatment, and that tumor size was reduced by over 50%.
The Nikbakht Lab concluded, ‘This investigation demonstrates the preclinical efficacy of CD206-binding peptides in a hematologic malignancy model. These findings offer a potential therapeutic strategy in the treatment of a disease that has limited pharmacologic treatment options and carries high morbidity and mortality in severe cases.’
The paper, entitled ‘A CD206 targeting peptide exhibits preclinical therapeutic efficacy in cutaneous T-cell lymphoma,’ is available at https://doi.org/10.1016/j.jid.2025.11.010
Riptide Bioscience, Inc., with laboratories in Vallejo, California, maintains an intensive program of research into peptide-based therapeutics. Contact: info@riptidebio.com
